TY - JOUR
T1 - Osteomalacia and osteitis fibrosa in a man ingesting aluminum hydroxide antacid
AU - Carmichael, Kim A.
AU - Fallon, Michael D.
AU - Dalinka, Murray
AU - Kaplan, Frederick S.
AU - Axel, Leon
AU - Haddad, John G.
N1 - Funding Information:
From the Endocrine Section, Department of Medicine and Departments of Pathology and Laboratory Medicine, Radiology, and Orthopedic Surgery, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania. This work was supported by National Institutes of Health Grants AM-28292 and RR-40. Requests for reprints should be addressed to Dr. John G. Haddad, Endocrine Section, Department of Medicine, University of Pennsylvania School of Medicine, 531 Johnson PaviliorVG2, Philadelphia, Pennsylvania 19104. Manuscript accepted July 11, 1983.
PY - 1984/6
Y1 - 1984/6
N2 - A 53-year-old man with a history of long-term aluminum hydroxide antacid ingestion reported diffuse bone pain and multiple stress fractures over a two-year period. An undecalcified transiliac bone biopsy specimen revealed osteomalacia with osteitis fibrosa; plasma parathyroid hormone and cyclic AMP levels were normal. Following withdrawal of antacids and treatment with calcium and phosphorus, an initially elevated plasma, 1,25-dihydroxyvitamin D level fell to within the normal range, accompanied by decreased bone pain, healed stress fractures, and increased axial bone mineral content as determined by computed tomography of lumbar trabecular bone. Phosphate deprivation and 1,25-dihydroxyvitamin D excess may contribute to the poor mineralization and exaggerated resorption of bone observed in this syndrome. The clinical, biochemical, radiologic, and histologic features of previously reported cases are reviewed. Early recognition of this syndrome is important, since appropriate therapy promotes skeletal remineralization and prevents morbidity.
AB - A 53-year-old man with a history of long-term aluminum hydroxide antacid ingestion reported diffuse bone pain and multiple stress fractures over a two-year period. An undecalcified transiliac bone biopsy specimen revealed osteomalacia with osteitis fibrosa; plasma parathyroid hormone and cyclic AMP levels were normal. Following withdrawal of antacids and treatment with calcium and phosphorus, an initially elevated plasma, 1,25-dihydroxyvitamin D level fell to within the normal range, accompanied by decreased bone pain, healed stress fractures, and increased axial bone mineral content as determined by computed tomography of lumbar trabecular bone. Phosphate deprivation and 1,25-dihydroxyvitamin D excess may contribute to the poor mineralization and exaggerated resorption of bone observed in this syndrome. The clinical, biochemical, radiologic, and histologic features of previously reported cases are reviewed. Early recognition of this syndrome is important, since appropriate therapy promotes skeletal remineralization and prevents morbidity.
UR - http://www.scopus.com/inward/record.url?scp=0021251270&partnerID=8YFLogxK
U2 - 10.1016/0002-9343(84)90871-4
DO - 10.1016/0002-9343(84)90871-4
M3 - Article
C2 - 6328994
AN - SCOPUS:0021251270
SN - 0002-9343
VL - 76
SP - 1137
EP - 1143
JO - The American journal of medicine
JF - The American journal of medicine
IS - 6
ER -